An Open-Label Trial of Methylphenidate Treating Sluggish Cognitive Tempo, Inattention, and Hyperactivity/Impulsivity Symptoms Among 6- to 12-Year-Old ADHD Children: What Are the Predictors of Treatment Response at Home and School?

  title={An Open-Label Trial of Methylphenidate Treating Sluggish Cognitive Tempo, Inattention, and Hyperactivity/Impulsivity Symptoms Among 6- to 12-Year-Old ADHD Children: What Are the Predictors of Treatment Response at Home and School?},
  author={S{\"u}meyra Fırat and Hesna Gul and Ayla Aysev},
  journal={Journal of Attention Disorders},
  pages={1321 - 1330}
Objective: This study investigated the effects of sluggish cognitive tempo (SCT), other psychiatric symptoms, age, dose, and pretreatment ADHD severity on methylphenidate (MPH) treatment response among ADHD children in both home and school. In addition, the predictors of the MPH-SCT treatment response were examined. Methods: One hundred eighty-five (6–12 years old) ADHD children who were treated with MPH included in the study. Results: MPH improved SCT total and SCT-Daydreaming scores both at… 

Tables from this paper

The Associations Between Sluggish Cognitive Tempo, Internalizing Symptoms, and Academic Performance in Children With Reading Disorder: A Longitudinal Cohort Study.
SCT has negative effects on anxiety and AP in children with RD among individuals with low ADHD-IN according to teacher report, and targeted treatment of SCT may provide substantial benefits.
A Preliminary Evaluation of the Utility of Sluggish Cognitive Tempo Symptoms in Predicting Behavioral Treatment Response in Children with Behavioral Difficulties
This preliminary investigation revealed that pre-treatment SCT symptoms only predicted a less robust treatment response to time out which was associated also with parent's perceptions of underlying working memory problems and other potential predictors largely failed to predict behavioral treatment response.
Systematic Review: Assessment of Sluggish Cognitive Tempo Over the Past Decade.
  • S. Becker
  • Psychology
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2020
Sluggish Cognitive Tempo and Daytime Sleepiness Mediate Relationships Between Sleep and Academic Performance
SCT symptoms are important for understanding how sleep difficulties affect academic performance in children, and sleep, daytime sleepiness, and SCT are interrelated but distinct factors that affect children's academic performance.
“My mom calls it Annaland”: A Qualitative Study of Phenomenology, Daily Life Impacts, and Treatment Considerations of Sluggish Cognitive Tempo
Insight into possible intervention targets as provided by youth and parents directly impacted by SCT is offered, with SCT fostering creativity/imagination and a break from stressors while also negatively impacting daily functioning.
Atomoxetine might be more effective in improving sluggish cognitive tempo symptoms after switching from methylphenidate: A case report
Although there is no proven evidence regarding pharmacotherapy of Sluggish Cognitive Tempo (SCT), we experienced atomoxetine had more effects in decreasing SCT symptoms after switching from
Sluggish Cognitive Tempo and Attention Deficit Hyperactivity Disorder: Similarities and Differences
2Balıkesir Atatürk Şehir Hastanesi, Tıbbi Genetik Kliniği, Balıkesir, Türkiye 3Ege Üniversitesi Tıp Fakültesi, Biyoistatistik Anabilim Dalı, İzmir, Türkiye 4Medical Park Hastanesi, Çocuk ve Ergen Ruh


Do sluggish cognitive tempo symptoms predict response to methylphenidate in patients with attention-deficit/hyperactivity disorder-inattentive type?
The findings corroborate previous phenotypic data suggesting that SCT symptoms do not define a clinically relevant type of ADHD-I.
Sluggish Cognitive Tempo as a Possible Predictor of Methylphenidate Response in Children With ADHD: A Randomized Controlled Trial.
OBJECTIVE To examine whether sluggish cognitive tempo (SCT) symptomatology moderates dose response to methylphenidate and whether the impact of SCT on medication response is distinct from
Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
A post hoc analysis of a 16-week placebo-controlled, double-blind randomized phase of a previously reported atomoxetine study in children aged 10–16 years with ADHD+D, Dyslexia-only, or ADHD-only (no placebo arm) to determine factors affecting improvement of SCT in children with attention-deficit/hyperactivity disorder with dyslexia.
High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder
Baseline cognitive impulsivity (as measured by the CCPT) can predict response of ODD to MPH treatment in ADHD/ODD patients.
Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.
Study findings suggest that MPH treatment significantly improved mood and emotional symptoms associated with DMDD comorbid with ADHD, and good tolerability in this open-label pilot study supports further research into the use of MPH as a first-line treatment for D MDD.
Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder.
Results support the clinical utility of MPH in the treatment of the PI subtype and provide no evidence of differences in response between the subtypes.
Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
This is the first study to report significant effects of any medication on SCT, and atomoxetine treatment improved ADHD symptoms inSubjects with ADHD+D and ADHD-only, but not in subjects with dyslexia-only without ADHD.
The effect of methylphenidate treatment on suspiciousness in children with ADHD alone or comorbid with ODD
In addition to the beneficial effect of MPH treatment on ADHD and ODD symptoms it also diminishes suspiciousness, according to the small sample size further studies are needed to confirm the present results.
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
In children with ADHD-CT, the most common subtype of ADHD, increasing doses of stimulant medication were associated with increased improvement of inattention and hyperactivity symptoms and less benefit was derived from higher doses.
The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder.
A correlation exists between MPH-related improvement in ADHD symptoms and between more empathy in children with ADHD not comorbid with ODD.